Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
Jabbour, E.J. (The University of Texas MD Anderson Cancer Center)
Kantarjian, Hagop M. (The University of Texas MD Anderson Cancer Center)
Goekbuget, N. (Goethe University)
Shah, B.D. (Moffitt Cancer Center (Tampa, Estats Units d'Amèrica))
Chiaretti, S. (Università degli Studi di Roma "La Sapienza")
Park, J.H. (Memorial Sloan Kettering Cancer Center)
Rijneveld, A.W. (Erasmus MC Cancer Institute)
Gore, L. (University of Colorado Cancer Center)
Fleming, S. (Monash University)
Logan, A.C. (University of California San Francisco)
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Menne, T.F. (The Newcastle upon Tyne Hospitals and Newcastle University)
Mezzi, K. (Amgen Inc)
Zaman, F. (Amgen Inc)
Velasco, K. (Amgen Inc)
Boissel, Nicolas (Saint-Louis Hospital)
Universitat Autònoma de Barcelona

Date:	2024
Abstract:	This narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philadelphia (Ph) chromosome-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in the frontline setting and to describe the latest clinical research using the bispecific T-cell-engaging immunotherapy blinatumomab in the first-line treatment setting. Current standard-of-care chemotherapeutic backbones for newly diagnosed Ph-negative BCP-ALL are based on the same overarching treatment principle: to reduce disease burden to undetectable levels and maintain lasting remission. The adult treatment landscape has progressively evolved following the adoption of pediatric-inspired regimens. However, these intense regimens are not tolerated by all, and high-risk patients still have inferior outcomes. Therefore, designing more effective and less toxic strategies remains key to further improving efficacy and safety outcomes. Overall, the treatment landscape is evolving in the frontline, and integration of blinatumomab into different standard frontline regimens may improve overall outcomes with a favorable safety profile.
Grants:	Agència de Gestió d'Ajuts Universitaris i de Recerca 2021/SGR-00447
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Subject:	Antibodies, Bispecific ; Humans ; Philadelphia Chromosome ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Published in:	Blood Cancer Journal, Vol. 14 Núm. 1 (december 2024) , p. 203, ISSN 2044-5385

DOI: 10.1038/s41408-024-01179-4
PMID: 39562780

16 p, 1.4 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles